Small-cap Virpax (VRPX) Up 100% Today to Push Weekly Gains to Over 500% After Receiving FDA Guidance on SARS and Flu Treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. IBM
9. HOOD
10. DFTX

Go back to Small-cap Virpax (VRPX) Up 100% Today to Push Weekly Gains to Over 500% After Receiving FDA Guidance on SARS and Flu Treatment

Virpax® Pharmaceuticals Receives FDA Response and Guidance on MMS019

August 17, 2021 9:00 AM EDT

--  Company to Pursue Prophylactic Treatment Against SARS and Influenza for Daily Use as an OTC Product --

BERWYN, Pa.--(BUSINESS WIRE)-- Virpax® Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has received a written pre-investigational new drug (pre-IND) response from the U.S. Food and Drug Administration (FDA) for MMS019, its patented and proprietary high-density molecular masking spray under development for use as an anti-viral barrier product. Virpax... More